Neko Health, the body-scanning startup founded by Spotify's Daniel Ek, will open its first U.S. office and clinic in the heart of Manhattan's SoHo on September 24. According to a report from TechCrunch, the company has a waitlist of 25,000 New Yorkers and will open at 300 Lafayette Street.
XOOMAR Intelligence
Analyst Take
This U.S. launch follows the company's $700 million Series C financing round last month, which valued Neko Health at approximately $7 billion. The expansion pits Ek's preventative health model directly against a crowded field of wellness startups and America's entrenched, reactive healthcare system.
The European Health Scan Giant Lands in New York
The opening is the concrete next step in the company's stated U.S. ambition. Neko Health was founded by Ek and Hjalmar Nilsonne, who serves as CEO, in 2018 but launched publicly in 2023. It has since opened eight clinics in the UK and Sweden, where it says 100,000 people have already had scans.
“We’ve gone into markets where health care is free, and hundreds of thousands of people line up in a queue” to pay for a scan, Daniel Ek told the New York Times. “That also captures the imagination.”
The New York outpost is Neko's first beachhead outside of Europe. The company's model pairs proprietary full-body scanning hardware with bloodwork and wearable device data for a comprehensive, preventative health assessment aimed at early detection of conditions like skin cancer, heart disease, and diabetes.
Can a $7 Billion Premium Model Survive the US Market?
Neko Health's U.S. arrival creates an immediate market tension: selling a premium, out-of-pocket service to consumers accustomed to annual physicals largely covered by insurance.
The pilot in New York will test direct consumer demand outside of a European-style public health framework.
- The Neko Model: Pay directly for a 60-minute scan and analysis. Current UK pricing is £299 (roughly $400). U.S. pricing is not yet set.
- Traditional US Care: Reactive, insurance-covered intervention after symptoms appear. Preventative scans are typically not covered unless deemed medically necessary.
The company's traction in Europe is undeniable. Over 350,000 people total have either been scanned or are on waitlists. High-profile backers in its last round include Mark Zuckerberg, Maria Sharapova, will.i.am, and Thierry Henry. But the U.S. market is far more fragmented and crowded, with companies like Fountain Life, Prenuvo, and Midjourney all vying for the same longevity-focused, biohacking demographic, illustrating a broader trend of startups entering crowded tech markets—including the high-stakes AI sector, as seen when Elon Musk buys a code editor—to capitalize on existing frustrations. As we reported in Fusion Startup Cash Flood Goes to Elite Few, massive funding rounds are not always indicative of mainstream commercial success.
Neko’s New York Gamble: Luxury Convenience or Healthcare Revolution?
The Manhattan launch answers the "where" but leaves critical strategic questions unanswered.
The Marketing Conundrum Will Neko position itself as a luxurious convenience for the wealthy, or a fundamental public health tool? Its SoHo address, nestled in luxury shopping districts, suggests the former. Yet Ek's comments frame the mission as a preventative revolution.
The Scale Question Is New York a one-off experiment or the first domino in a capital-intensive nationwide rollout? The $700 million war chest and its $7 billion valuation imply massive ambitions, but building and staffing clinics across the U.S. is a far more complex and regulated undertaking than the European expansion. The company has so far only confirmed New York for 2026.
Proof of Value Ultimately, early U.S. customer reviews will decide the narrative. Will testimonials focus on novel data insights and early detection stories, like that of Calm founder Alex Tew, who posted that a Neko scan found a malignant mole? Or will they critique the price-to-value ratio? As seen in Google Pixel 11's First Price Cut Lands Days After Launch, even well-funded tech products face immediate market pressure on perceived value.
The company's statement that 75% of returning members whose scans flagged a serious condition now have it under control is a powerful claim, but its real-world impact in the U.S. is untested.
XOOMAR Analysis Neko Health's launch is less about introducing a new tech product and more about testing whether a European-originated, data-first health philosophy can disrupt the American status quo. The 25,000-person New York waitlist shows demand exists. The next month will reveal if Neko can convert that curiosity into a sustainable business, or if it becomes another niche player in the high-end wellness space. Watch the announced pricing and the company's next city announcement after September 24. The real measure of its $7 billion valuation will be how fast it moves beyond a single, posh Manhattan address.
Impact Analysis
- This marks a major test of a premium, direct-to-consumer preventative health model in the U.S., challenging the norm of insurance-covered annual physicals.
- The launch signals significant venture capital interest ($7B valuation) in shifting healthcare from reactive treatment to proactive, data-driven early detection.
- With a waitlist of 25,000 in NYC, it reveals strong consumer demand for accessible, high-tech health diagnostics outside traditional systems.
Neko Health Funding & Valuation (2026)
Primary Sources & Disclosures
Written by
XOOMAR Insights Team
Research and Editorial Desk
The XOOMAR Insights Team pairs automated research with human editorial judgment. We track hundreds of sources across technology, fintech, trading, SaaS, and cybersecurity, cross-check the facts, and explain what happened, why it matters, and what to watch next. We do not just rewrite headlines. Every article is fact-checked and scored for reliability before it goes live, and we link back to the original sources so you can verify anything yourself.
